Endo Inc. (NDOI)
OTCMKTS · Delayed Price · Currency is USD
21.33
+0.03 (0.14%)
Apr 17, 2025, 4:00 PM EDT

Endo Inc. Company Description

Endo Inc., a specialty pharmaceutical company, develops, manufactures, markets, and sells various pharmaceutical products in the United States and internationally.

The company offers products for the treatment of conditions in urology, orthopedics, and endocrinology.

It is involved in the developing additional indications for XIAFLEX in clinical development, including plantar fibromatosis and plantar fasciitis, as well as others are in pre-clinical development, including arthrofibrosis of the knee following knee arthroplasty.

The company offers ADRENALIN, a non-selective alpha and beta adrenergic agonist indicated for emergency treatment of certain allergic reactions, including anaphylaxis; VASOSTRICT, a product indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines; and APLISOL, a sterile aqueous solution of a purified protein derivative for intradermal administration for aid in the diagnosis of tuberculosis.

In addition, it offers SUPPRELIN LA, a soft flexible 12-month hydrogel implant based on hydrogel polymer technology that delivers histrelin acetate, a gonadotropin-releasing hormone agonist, and is indicated for the treatment of CPP in children; AVEED, a novel long-acting testosterone undecanoate for injection for the treatment of hypogonadism; TESTOPEL, a unique, long-acting implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; and EDEX, a penile injection used to treat erectile dysfunction caused by conditions affecting nerves, blood vessels, emotions and/or a combination of factors.

It provides solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, patches, powders, ophthalmics, and sprays.

The company was founded in 1997 and is headquartered in Malvern, Pennsylvania.

Endo Inc.
Country United States
Founded 1997
Industry Drug Manufacturers - Specialty & Generic
Sector Healthcare
Employees 3,116
CEO Scott Hirsch

Contact Details

Address:
9 Great Valley Parkway
Malvern, Delaware 19355
United States
Phone 484-216-0000
Website endo.com

Stock Details

Ticker Symbol NDOI
Exchange OTCMKTS
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
SIC Code 2834

Key Executives

Name Position
Scott A. Hirsch Interim Chief Executive Officer and Director
Mark T. Bradley Executive Vice President and Chief Financial Officer
Matthew Joseph Maletta Executive Vice President, Chief Legal Officer and Company Secretary
Patrick A. Barry Executive Vice President and President of Global Commercial Operations
Dr. James Patrick Tursi M.D. Executive Vice President of Global Research and Development
Frank B. Raciti Vice President, Controller and Chief Accounting Officer
Cheryl Stouch Senior Vice President of Information Technology and Chief Information Officer
Laure E. Park Senior Vice President of Investor Relations and Corporate Affairs
Susan Williamson CPA Senior Vice President and Chief Compliance Officer
Tracy Basso Chief Human Resources Officer